Erythropoietin ameliorates early ischemia-reperfusion injury following the Pringle maneuver

Table 1 Patients' backgrounds

	STRD (n = 9)	EPO1 (n = 10)	EPO2 (n = 8)	P-value
Age (yr)	62.7 ± 10.6	62.1 ± 15.8	69.3 ± 7.8	0.395
Male/female	6/3	7/3	6/2	0.976
ICG R15 (%)	14.0 ± 8.8	10.7 ± 4.8	11.3 ± 5.2	0.854
Diagnosis (HCC/others)	6/3	6/4	4/4	0.890
Operation time (min)	322 ± 122	245 ± 83	299 ± 57	0.105
Pringle time (min)	43.9 ± 26.8	39.2 ± 21.2	53.8 ± 15.1	0.153
Operative blood loss (mL)	674 (70-3673)	469 (66-1900)	356 (228-1362)	0.386
Operative method (anatomical/nonanatomical)	6/3	4/6	6/2	0.321

HCC: Hepatocellular carcinoma; STRD: Steroid group; EPO: Erythropoietin.

Table 2 Postoperative complications

	Complication	Frequency (%)
STRD (n = 10)	n = 2	20
	Prolonged ascites
	Pleural effusion
EPO1 (n = 10)	0	0
EPO2 (n = 8)	0	0

STRD: Steroid group; EPO: Erythropoietin.